Compare Medpace Holdings Inc (MEDP) vs Taskus Inc (TASK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Taskus Inc — how do they compare? Medpace Holdings Inc trades at $611.57 (market cap $16.82B), while Taskus Inc trades at $8.15 (market cap $723.41M). The key difference: Medpace Holdings Inc is far larger — about 23.3× Taskus Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Taskus Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Taskus Inc for 34 Days on average.
| MEDP | TASK | |
|---|---|---|
Market Cap | $16.82B | $723.41M |
Volume | 223,093 | 201,303 |
Sector | Health | Technology |
52-Week High | $630.19 | $14.69 |
52-Week Low | $393.42 | $4.57 |
Typical Hold Time | 14 Days | 34 Days |
Enterprise Value | $16.44B | $1.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
TaskUs trades at $8.14, up 3.17% with mixed technical signals showing bearish moving averages but neutral oscillators. The company demonstrates strong fundamentals with revenue growth to $1.18B in 2025 and net income margin expanding to 8.75%. Recent Q2 2026 earnings beat expectations with $0.33 EPS versus $0.29 expected, though Q1 2026 missed estimates. Valuation metrics appear attractive with P/E of 6.8 and P/S of 0.6, suggesting potential undervaluation.
The stock presents a compelling value opportunity given its low valuation multiples and strong profitability metrics, though technical weakness and competitive pressures in AI services create near-term headwinds. Analyst consensus remains positive with a $9.33 price target representing 15% upside potential from current levels, supported by institutional accumulation including Dimensional Fund Advisors' 12.8% position increase in Q1 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
